Lantheus Presents Groundbreaking Florbetaben F 18 Findings
Lantheus Holdings, Inc. (NASDAQ: LNTH), a pioneering name in the world of radiopharmaceuticals, is on the verge of presenting vital new research involving florbetaben F 18 at an esteemed conference dedicated to Alzheimer's disease. This significant event is known as the Clinical Trials on Alzheimer's Disease (CTAD) 2025 conference, and it will take place from December 1st through December 4th in sunny San Diego, California.
Details of the Presentation
During the event, attendees will have the chance to learn more about the promising data surrounding florbetaben F 18. Key details of this notable poster presentation are outlined below:
Poster Presentation
Date and Time: Wednesday, December 3, 2025; 7:15 AM – 5:30 PM PT
Session Number: 06
Session Title: Clinical Trials: Imaging
Poster Title: Florbetaben binding to amyloid plaques is unaffected by amyloid-targeting antibodies lecanemab and donanemab
Poster Number: P184
Presenter: Marianne Chapleau, representing Life Molecular Imaging
About Neuraceq (Florbetaben F 18 injection)
Neuraceq is a revolutionary product tailored for positron emission tomography (PET) imaging of the brain. It’s designed to estimate the density of amyloid beta neuritic plaques. This crucial tool is aimed at aiding adults experiencing cognitive decline by evaluating conditions such as Alzheimer's disease (AD) and other cognitive impairments.
Indications
The uses of Neuraceq are vital and include:
- Evaluating Alzheimer’s disease and various causes of cognitive decline.
- Assisting in identifying patients eligible for amyloid beta-directed therapies, according to the associated prescribing information of therapeutic products.
Important Safety Information
While Neuraceq is established as an effective imaging agent, there are crucial considerations regarding its interpretation and potential errors:
Risk for Image Interpretation and Errors
Errors in estimating amyloid beta neuritic plaques can arise during image interpretation. Thus, the dependence on clinical data during this interpretation hasn’t been thoroughly validated, which means it could lead to inaccuracies. Factors such as severe brain atrophy and motion artifacts can also distort imaging results, thereby complicating the differentiation between gray and white matter on a scan.
Radiation Safety
Neuraceq was evaluated for its radiation safety, indicating that it contributes to a patient's overall long-term cumulative radiation exposure—an aspect associated with an increased cancer risk. Effective safety measures should be taken by healthcare professionals and patients, including sufficient hydration pre- and post-administration and frequent voiding following the procedure.
Common Adverse Reactions
The safety profile of Neuraceq was determined from a study involving over a thousand administrations across numerous patients. Among the reported reactions, minor injection site reactions were the most common, with instances of pain (3.4%), erythema (1.7%), and irritation (1.1%).
About Lantheus
With a commitment to enhancing patient outcomes, Lantheus is at the forefront of radiopharmaceutical innovation. Operating for nearly 70 years, Lantheus delivers solutions that enable healthcare professionals to locate and treat diseases effectively. The company is headquartered in Massachusetts and has expanded its reach globally with offices in various countries, including Germany, Canada, and the United Kingdom.
Contact Details
Lantheus
Mark Kinarney
Vice President, Investor Relations
978-671-8842
ir@lantheus.com
Melissa Downs
Executive Director, External Communications
646-975-2533
media@lantheus.com
Frequently Asked Questions
What is Lantheus's main focus?
Lantheus focuses on developing radiopharmaceuticals to help clinicians detect and treat diseases effectively.
What is Neuraceq?
Neuraceq is a radiopharmaceutical product used in PET imaging to assess amyloid beta plaque density in the brain.
What will be presented at CTAD 2025?
New findings related to florbetaben F 18 and its interaction with amyloid-targeting antibodies will be presented.
What are common side effects of Neuraceq?
Common adverse reactions include injection site pain and minor irritation, but severe reactions are rare.
How long has Lantheus been in operation?
Lantheus has been a leader in radiopharmaceuticals for nearly 70 years, evolving in technology and treatments.
